Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesNov 14 17:12 ET · Ratings

Enlivex Therapeutics Price Target Maintained With a $13.00/Share by D. Boral Capital

Dow JonesNov 14 17:12 ET · Ratings

Enlivex Therapeutics Analyst Ratings

BenzingaNov 14 17:00 ET · Ratings

Express News | Enlivex Therapeutics Ltd - Psoriatic Arthritis Treatment Market Projected to Reach $20.5 Billion by 2032

ReutersNov 14 08:00 ET

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients With Psoriatic Arthritis

GlobeNewswireNov 14 08:00 ET

Express News | Enlivex Announces Enrollment And Dosing Of First 10 Patients In The Randomized Phase II Stage Of Its Allocetra Trial For Patients With Moderate To Severe Knee Osteoarthritis

BenzingaNov 12 08:06 ET